OPM
Develops proprietary PEKK-based materials and processes for high-performance additive manufacturing, producing FDA-cleared patient-specific implants and aerospace components.
- CEO / Founder
- Scott DeFelice
- Team Size
- 21-50
- Stage
- Active
- Total Funding
- $10M
- Latest Round
- Venture Round
- Key Investors
- Hexcel Corporation
Technology & Products
Key Products
OXPEKK® PEKK polymers; OsteoFab® patient-specific implants; OXFAB® industrial parts; High-performance additive manufacturing (HPAM™) services
Technological Advantage
Proprietary OXPEKK® composition and HPAM™ process achieve higher performance (e.g., B-Basis allowables for aerospace) and regulatory clearances (6 FDA 510(k)s), protected by patents.
Differentiation
Value Proposition
Enables production of lightweight, strong, and biocompatible 3D-printed parts that replace metal, reducing weight by up to 70% and cutting lead times from months to weeks for custom implants and aerospace components.
How They Differentiate
OPM's PEKK-based materials offer superior strength-to-weight ratio and biocompatibility vs. standard polymers, with exclusive FDA clearances for 3D-printed implants and aerospace qualifications that competitors lack.
Market & Competition
Target Customers
Medical device manufacturers, aerospace OEMs, industrial companies requiring high-performance thermoplastic parts
Industry Verticals
Medical; Aerospace; Defense; Industrial; Energy
Competitors
Rowland Technologies; Polymer Resources Ltd.; Impossible Objects
Growth & Milestones
Growth Metrics
Revenue estimated $12M-$15M; 6 FDA 510(k) clearances for implants; ISO 13485, AS9100C certifications.
Major Milestones
Founded in 2000; First FDA 510(k) clearance for 3D-printed polymeric implants (2013); Hexcel acquisition of Aerospace & Defense business (2017); Partnership with SINTX for composite coatings (2022); Creation of separate orthopedic business entity (2023)
Notable Customers
Boeing; Sovereign Medical Ltd